Basal Ganglia

Caudate nucleus:

• A C-shaped nucleus with a head, body, and tail, closely following the curve of the lateral ventricle (the head bulges into the frontal horn, the tail curves down into the temporal horn), together with the putamen, forms the striatum, the basal ganglia's main input structure.

Putamen:

• Located lateral to the globus pallidus, together with the caudate nucleus forming the striatum; together with the globus pallidus, forms the lentiform (lenticular) nucleus: the putamen and caudate are developmentally/functionally a single structure, artificially separated by the fibres of the internal capsule passing between them (visible as thin grey matter bridges connecting the two on coronal sections).

Globus pallidus:

• Divided into external (GPe) and internal (GPi) segments, medial to the putamen; the basal ganglia's main output structure (alongside the substantia nigra pars reticulata), sending inhibitory output to the thalamus.

Subthalamic nucleus:

• A small nucleus located below the thalamus (within the subthalamus), functionally integrated into the basal ganglia circuitry as a key excitatory relay within the indirect pathway, its lesion produces hemiballismus (see Clinical Correlations).

Substantia nigra:

• Located in the midbrain, divided into pars compacta (dopaminergic neurons, projecting to the striatum, the nigrostriatal pathway, degeneration of which underlies Parkinson's disease) and pars reticulata (functionally analogous to the globus pallidus internal segment, contributing to basal ganglia output).

With the cortex:

• The basal ganglia receive their main input from the cerebral cortex (predominantly motor and premotor areas, but also sensory and association cortex) via the striatum (caudate + putamen), and send output back to the cortex indirectly, via the thalamus, forming a cortico-striato-pallido-thalamo-cortical loop, the fundamental circuit architecture underlying basal ganglia function.

With the thalamus:

• The basal ganglia's output nuclei (GPi and substantia nigra pars reticulata) project to specific thalamic nuclei (predominantly the ventral anterior and ventral lateral nuclei), which then relay back to the motor/premotor cortex, closing the loop.

With motor pathways:

• The basal ganglia do not project directly to the spinal cord or brainstem motor neurons (unlike the corticospinal/corticobulbar and extrapyramidal tracts), their influence on movement is exerted entirely indirectly, by modulating the activity of the motor cortex (via the thalamus) before the cortex itself generates descending motor commands; this is a critical distinguishing point from the true "extrapyramidal" descending tracts, though the basal ganglia are still often colloquially (if technically imprecisely) discussed under an "extrapyramidal system" heading given their shared clinical relevance to movement disorders.

• Two parallel pathways through the basal ganglia, both originating in the striatum, with opposite net effects on movement: a simplified but pedagogically essential framework for understanding basal ganglia physiology at the level required for anatomical/clinical correlation (full receptor pharmacology and detailed physiology are beyond gross anatomical scope).

Direct pathway:

• Striatum → GPi/substantia nigra pars reticulata (directly, via an inhibitory connection) → thalamus.
• Net effect: striatal activation inhibits the GPi's normally tonic inhibitory output to the thalamus, this "disinhibition" increases thalamic excitatory output to the motor cortex, facilitating movement.

Indirect pathway:

• Striatum → GPe (inhibitory) → subthalamic nucleus (disinhibited, therefore more active) → GPi/substantia nigra pars reticulata (excitatory) → thalamus.
• Net effect: striatal activation, via this longer route, increases the GPi's inhibitory output to the thalamus, suppressing unwanted/competing movements.

• Overall functional summary: The direct pathway facilitates intended movement; the indirect pathway suppresses unwanted competing movement, normal, smooth voluntary movement depends on the correct balance between these two opposing pathways, modulated by dopaminergic input from the substantia nigra pars compacta (which facilitates the direct pathway and suppresses the indirect pathway, via different dopamine receptor subtypes on striatal neurons), this dopaminergic balancing role is the direct anatomical basis for Parkinson's disease's pathophysiology.

Parkinsonism:

• Results from degeneration of the dopaminergic substantia nigra pars compacta neurons, reducing dopaminergic facilitation of the direct pathway and reduced suppression of the indirect pathway, the net effect is excessive GPi inhibitory output to the thalamus, reducing thalamocortical facilitation of movement, producing the classic clinical triad of bradykinesia (slowness of movement), rigidity (increased muscle tone), and resting tremor (classically "pill-rolling"), often with postural instability as a later feature, the anatomical/physiological basis directly explains why dopamine replacement therapy (levodopa) and, in advanced cases, deep brain stimulation (classically targeting the subthalamic nucleus or GPi) are effective treatments, both aiming to rebalance this disrupted direct/indirect pathway equilibrium.

Huntington disease:

• An inherited neurodegenerative condition causing early, selective loss of striatal neurons (particularly those of the indirect pathway, projecting to GPe), this selective early loss of indirect pathway inhibition produces the opposite physiological effect to Parkinson's disease (reduced indirect pathway suppression of movement), manifesting clinically as chorea (involuntary, irregular, dance-like movements), as the disease progresses and more widespread striatal degeneration occurs (eventually including direct pathway neurons), the clinical picture can evolve toward a more parkinsonian, bradykinetic phenotype in later stages.

Hemiballismus:

• Results from a lesion (classically a small lacunar infarct, given the region's vascular supply pattern) of the contralateral subthalamic nucleus: loss of this nucleus's normal excitatory drive to the GPi (a key indirect pathway component) reduces the GPi's inhibitory output to the thalamus, producing excessive thalamocortical facilitation and consequent violent, high-amplitude, flinging/ballistic involuntary movements, classically affecting one side of the body (contralateral to the lesion), a dramatic, distinctive movement disorder directly and specifically localising to this single small nucleus, making it one of the clearest lesion-to-symptom correlations in basal ganglia anatomy.